Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 254-256

  Kaatz, Glenn W ^a,b,d   Seo, Susan M ^a,b   Aeschlimann, Jeffrey R ^b,c   Houlihan, Heather H ^b,c   Mercier, Reneé Claude ^b,c   Rybak, Michael J ^a,b,c  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; PRODRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; ENDOCARDITIS, BACTERIAL; FLUOROQUINOLONES; MALE; NAPHTHYRIDINES; OUTCOME ASSESSMENT (HEALTH CARE); RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0031943898     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bonilla, H. F., L. T. Zarins, S. F. Bradley, and C. A. Kauffman. 1996. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Diagn. Microbiol. Infect. Dis. 26:17-21.
2. Brighty, K. E., and T. D. Gootz. 1997. The chemistry and biological profile of trovafloxacin. J. Antimicrob. Chemother. 39(Suppl. B):1-14.
3. Edelstein, P. H., M. A. Edelstein, J. Ren, R. J. Polzer, and R. P. Gladue. 1996. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 40:314-319.
4. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
5. Endtz, H. P., J. W. Mouton, J. G. den Hollander, N. van den Braak, and H. A. Verbrugh. 1997. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob. Agents Chemother. 41:1146-1149.
6. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
7. Kaatz, G. W., S. L. Barriere, D. R. Schaberg, and R. Fekety. 1987. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 31:527-530.
8. Kaatz, G. W., S. L. Barriere, D. R. Schaberg, and R. Fekety. 1987. The emergence of resistance to ciprofloxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. J. Antimicrob. Chemother. 20:753-758.
9. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1989. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 33:519-521.
10. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1990. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 34:257-260.
11. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1991. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 35:1547-1550.
12. Kaatz, G. W., S. M. Seo, K. C. Lamp, E. M. Bailey, and M. J. Rybak. 1992. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 36:1192-1197.
13. Kim, Y. S., Q. Liu, L. L. Chow, and M. G. Tauber. 1997. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1186-1189.
14. National Committee for Clinical Laboratory Standards. 1993. Approved standard M7-A3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. National Committee for Clinical Laboratory Standards, Villanova, Pa.
15. Neu, H. C., and N.-X. Chin. 1994. In vitro activity of the new fluoroquinolone trovafloxacin. Antimicrob. Agents Chemother. 38:2615-2622.
16. Schwenzer, K. S., C. J. Wang, and J. P. Anhalt. 1983. Automated fluorescence polarization immunoassay for monitoring vancomycin. Ther. Drug Monit. 5:341-345.
17. Sefton, A. M., J. P. Makelll, A. M. Rafay, A. Whiley, and J. D. Williams. 1997. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against gram-positive bacteria. J. Antimicrob. Chemother. 39(Suppl. B):57-62.
18. Simon, H. J., and E. J. Yin. 1970. Microbioassay of antimicrobial agents. Appl. Microbiol. 19:573-579.
19. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36:385-394.
20. Teng, R., T. E. Liston, and S. C. Harris. 1996. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J. Antimicrob. Chemother. 37:955-963.
21. Thadepalli, H., U. Reddy, S. K. Chuah, F. Thadepalli, C. Malilay, R. J. Polzer, N. Hanna, A. Esfandiari, P. Brown, and S. Gollapudi. 1997. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob. Agents Chemother. 41:583-586.
22. Verbist, L., and J. Verhaegen. 1996. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis. 15:683-685.
23. Vincent, J., J. Venitz, R. Teng, B. A. Baris, S. A. Willavize, R. J. Polzer, and H. L. Friedman. 1997. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J. Antimicrob. Chemother. 39(Suppl. B):75-80.